依立替康/氟尿嘧啶/亚叶酸三药联用治疗晚期胃癌的临床疗效观察

孙德好; 邵凌; 刘胜; 陈森林; 曹晓冰

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

依立替康/氟尿嘧啶/亚叶酸三药联用治疗晚期胃癌的临床疗效观察

孙德好, 邵凌, 刘胜, 陈森林, 曹晓冰

文章导航 > 药学实践与服务 > 2009 > 27(3): 189-192

孙德好, 邵凌, 刘胜, 陈森林, 曹晓冰. 依立替康/氟尿嘧啶/亚叶酸三药联用治疗晚期胃癌的临床疗效观察[J]. 药学实践与服务, 2009, 27(3): 189-192.

引用本文:

孙德好, 邵凌, 刘胜, 陈森林, 曹晓冰. 依立替康/氟尿嘧啶/亚叶酸三药联用治疗晚期胃癌的临床疗效观察[J]. 药学实践与服务, 2009, 27(3): 189-192.

SUN De-hao, SHAO Ling, LIU Sheng, CHEN Seng-lin, CAO Xiao-bing. Clinical study on combination chemotherapy with irinotecan,fluorouracil,and leucovorin in patients with advanced gastric carcinoma[J]. Journal of Pharmaceutical Practice and Service, 2009, 27(3): 189-192.

Citation:

SUN De-hao, SHAO Ling, LIU Sheng, CHEN Seng-lin, CAO Xiao-bing. Clinical study on combination chemotherapy with irinotecan,fluorouracil,and leucovorin in patients with advanced gastric carcinoma[J]. Journal of Pharmaceutical Practice and Service, 2009, 27(3): 189-192.

依立替康/氟尿嘧啶/亚叶酸三药联用治疗晚期胃癌的临床疗效观察

中国人民解放军第411医院普外科,上海200081

Clinical study on combination chemotherapy with irinotecan,fluorouracil,and leucovorin in patients with advanced gastric carcinoma

Department of General Surgery, 411th Hospital, PLA, Shanghai 200081, China

摘要: 目的:以紫杉醇/顺铂/氟尿嘧啶/亚叶酸(TAX/DDP/5-FU/LV)治疗方案为对照,探讨依立替康/氟尿嘧啶/亚叶酸(CPT-11/5-FU/LV)联合用药治疗进展期胃癌的疗效和安全性。方法:63例不能手术切除或已有转移的胃癌患者随机分为2组,治疗组:CTP-11 200 mg/d,静脉滴注2 h,第1天;LV200 mg/d,静脉滴注1 h,第1～5天;5-FU500 mg/d,静脉滴注2 h,第1～5天;对照组:TAX180 mg/d,静脉滴注2 h,第1天;DDP60 mg/d,静脉滴注1 h,第3天;LV200 mg/d,静脉滴注1 h,第1～5天;5-FU500 mg/d,静脉滴注2 h,第1～5天。两组均3周为1个周期,治疗至少2个周期,观察其有效率、生存期和毒副作用。结果:治疗组:可评价病例31例,其中CR0例,PR8例(25.8%),SD12例(38.7%),PD11例(35.5%),总有效率25.8%(8/31);对照组:可评价病例29例,其中CR0例,PR8例(27.6%),SD 12例(41.4%),PD 9例(31.0%),总有效率27.6%(8/29);两组有效率无显著性差异。治疗组和对照组中位生存期分别为7.7个月和8.3个月,1年生存率分别为34.4%和41.4%,两组比较无显著性差异。毒副作用主要为中性粒细胞下降、肝功能损伤、神经毒性、恶心、呕吐、腹泻等,多表现为Ⅰ、Ⅱ度,治疗组的腹泻发生率显著高于对照组;Ⅲ、Ⅳ度反应主要为中性粒细胞下降及神经毒性,治疗组发生率显著低于对照组。没有出现治疗相关性死亡。结论:CPT-11/5-FU/LV静滴给药是治疗进展期胃癌的有效化疗手段,毒性反应较低,但合理剂量和疗程还需进一步的大样本治疗观察。
- 依立替康 /
- 氟尿嘧啶 /
- 紫杉醇 /
- 顺铂 /
- 胃癌 /
- 化疗
Abstract: Objective :To investigate the efficacy and safety of irinotecan(CPT-11) plus fluorouracil(5-FU) and leucovorin(LV) in patients with advanced gastric carcinoma,in reference to those of paclitaxel(TAX) and cisplatin(DDP) combined with 5-FU and LV. Methods :63 Patients with untreated advanced gastric carcinoma were randomly enrolled into treatment group and control group.The treatment group were treated with CTP-11 200 mg on day 1,LV 200 mg and 5-FU 500 mg on day 1～5 while the control group were given TAX 180 mg on day 1,DDP 60mg on day 3,LV 200 mg and 5-FU 500 mg on day 1～5.Both regimens were repeated every 3 weeks.All the patients received at least two treatments and were evaluable for response rate,survival time,and adverse effect. Results :In 31 evaluable patients in treatment group,CR 0 case,PR 8 cases(25.8 %),SD 12 cases(38.7 %),and PD 11 cases(35.5 %).The response rate was 25.8 %(8/31).In 29 evaluable patients in control group,CR 0 case,PR 8 cases(27.6 %),SD 12 cases(41.4 %),and PD 9 cases(31.0 %).The response rate was 25.8 %(8/31).No significant difference was found in terms of response rate between two groups.The median survival and 1-year survival rates were 7.7 and 8.3 months,and 34.4 % and 41.4 % for both groups,respectively.There was no significant difference between two groups.The most common drug-related adverse effects,mainly grade Ⅰ and Ⅱ,included neutropenia,hepatic toxicity,neurotoxicity,diarrhea,nausea,and vomiting.The incidence rate of diarrhea in treatment group was significantly higher than that in control group.Adverse effects of grade Ⅲ and Ⅳ rested on neutropenia and neurotoxicity,and the incidence rate in treatment group was significantly lower than that in control group.No treatment-related death occurred. Conclusion :Intravenous drip of CPT-11/5-FU/LV seems an active approach for untreated advanced gastric carcinoma with tolerated side effects.Further extensive investigations concerning the dose and course of treatment are demand.
- irinotecan /
- fluorouracil /
- paclitaxel /
- cisplatin /
- gastric carcinoma /
- chemotherapy

[1]	陈炳辰, 于恩达. 增强紫杉醇对结直肠癌化疗疗效的研究进展 . 药学实践与服务, 2020, 38(6): 501-505. doi: 10.12206/j.issn.1006-0111.202007031
[2]	胡朝奇. 硅橡胶质量参数与氟尿嘧啶植入剂释放度的相关性研究 . 药学实践与服务, 2019, 37(1): 65-68. doi: 10.3969/j.issn.1006-0111.2019.01.015
[3]	林莉莉, 黄爱文, 林美钦, 方婕, 沈钦勇, 宋洪涛. 替吉奥单药或联合铂类治疗晚期非小细胞肺癌患者疗效与安全性的Meta评价 . 药学实践与服务, 2019, 37(6): 563-570. doi: 10.3969/j.issn.1006-0111.2019.06.018
[4]	程丹, 陈建明. 反相高效液相色谱法同时测定大鼠血浆中紫杉醇硬脂酸酯及其活性代谢产物紫杉醇的含量 . 药学实践与服务, 2018, 36(3): 224-227,273. doi: 10.3969/j.issn.1006-0111.2018.03.007
[5]	杨姣, 陈君君, 张湘奇, 张婧娴, 韩永龙. 消癌平注射液联合紫杉醇对人卵巢癌SK-OV-3细胞增殖及裸鼠异位移植瘤生长的作用 . 药学实践与服务, 2017, 35(6): 516-519,529. doi: 10.3969/j.issn.1006-0111.2017.06.009
[6]	张琦, 赵文萃, 刘洋, 张公良, 成念, 侯吉华. 疏水改性白及多糖自组装载紫杉醇纳米粒子在大鼠体内药动学研究 . 药学实践与服务, 2017, 35(6): 504-507. doi: 10.3969/j.issn.1006-0111.2017.06.006
[7]	成念, 赵文萃, 张琦, 王艳萍, 韩丹, 肖轩昂. 用疏水改性的白及多糖制备载紫杉醇纳米粒并对其表征 . 药学实践与服务, 2017, 35(1): 48-53. doi: 10.3969/j.issn.1006-0111.2017.01.012
[8]	王洁, 黄岩, 张川, 马兴元, 常文军, 陆一鸣. 氟尿嘧啶对结直肠癌RKO细胞SHP2基因表达的影响 . 药学实践与服务, 2017, 35(6): 512-515. doi: 10.3969/j.issn.1006-0111.2017.06.008
[9]	王可兴, 秦翠英, 韩静, 李荣丽, 陈仁财. 紫杉醇自微乳滴丸的制备及体外释放考察 . 药学实践与服务, 2016, 34(4): 330-333. doi: 10.3969/j.issn.1006-0111.2016.04.012
[10]	纪松岗, 吴琼, 朱臻宇, 董昕, 洪战英, 柴逸峰. 左卡尼汀缓解顺铂造成急性肾损伤的血清代谢组学研究 . 药学实践与服务, 2015, 33(5): 429-433. doi: 10.3969/j.issn.1006-0111.2015.05.012
[11]	陈维中, 蔡靖斌, 陈晓兰, 陈瑞奇, 李夏静, 廖联明. 汉黄芩素与氟尿嘧啶联用抗人肝癌细胞Hep-G2作用的拮抗效应研究 . 药学实践与服务, 2015, 33(5): 411-414. doi: 10.3969/j.issn.1006-0111.2015.05.007
[12]	韦平艳, 苑旺, 杨峰, 崔黎丽. 驻极体氟尿嘧啶凝胶贴剂的制备研究 . 药学实践与服务, 2015, 33(3): 217-220. doi: 10.3969/j.issn.1006-0111.2015.03.007
[13]	严建维. 左卡尼汀预防紫杉醇周围神经毒性的临床观察 . 药学实践与服务, 2014, 32(5): 372-373. doi: 10.3969/j.issn.1006-0111.2014.05.016
[14]	何志高, 鲍思蔚, 翟晓波. 吉西他滨或长春瑞滨联合顺铂治疗晚期非小细胞肺癌的系统评价 . 药学实践与服务, 2012, 30(2): 131-136. doi: 10.3969/j.issn.1006-0111.2012.02.015
[15]	何志高, 严俊, 陈国涵, 鲍思蔚, 翟晓波, 金丽, 施燕. 长春瑞滨(NP)或吉西他滨(GP)联合顺铂治疗晚期非小细胞肺癌的成本效用研究 . 药学实践与服务, 2012, 30(6): 462-463,480. doi: 10.3969/j.issn.1006-0111.2012.06.020
[16]	刘懿萱, 章琎, 陈盛新, 李捷玮. 三种化疗方案治疗进展期胃癌的成本效果分析 . 药学实践与服务, 2007, (2): 117-120.
[17]	陆振东, 张戈. 苦参素对胃癌细胞株MKN-54产生金属基质蛋白酶的抑制作用 . 药学实践与服务, 2006, (3): 147-149.
[18]	曹国建, 丁洁卫, 唐志华, 陈洪亮. 全肠外营养对胃癌病人术后的疗效观察 . 药学实践与服务, 2003, (1): 6-7.
[19]	张清林, 王爱平. 紫杉醇对大鼠的一般生殖毒性作用 . 药学实践与服务, 1996, (4): 199-201.
[20]	朱全刚, 魏水易. 抗肿瘤新药紫杉醇 . 药学实践与服务, 1995, (1): 12-14.

点击查看大图

计量

文章访问数: 1943
HTML全文浏览量: 181
PDF下载量: 294
被引次数: 0

依立替康/氟尿嘧啶/亚叶酸三药联用治疗晚期胃癌的临床疗效观察

中国人民解放军第411医院普外科,上海200081

收稿日期: 2009-03-18

关键词:

依立替康 /

氟尿嘧啶 /

紫杉醇 /

顺铂 /

胃癌 /

化疗

摘要: 目的:以紫杉醇/顺铂/氟尿嘧啶/亚叶酸(TAX/DDP/5-FU/LV)治疗方案为对照,探讨依立替康/氟尿嘧啶/亚叶酸(CPT-11/5-FU/LV)联合用药治疗进展期胃癌的疗效和安全性。方法:63例不能手术切除或已有转移的胃癌患者随机分为2组,治疗组:CTP-11 200 mg/d,静脉滴注2 h,第1天;LV200 mg/d,静脉滴注1 h,第1～5天;5-FU500 mg/d,静脉滴注2 h,第1～5天;对照组:TAX180 mg/d,静脉滴注2 h,第1天;DDP60 mg/d,静脉滴注1 h,第3天;LV200 mg/d,静脉滴注1 h,第1～5天;5-FU500 mg/d,静脉滴注2 h,第1～5天。两组均3周为1个周期,治疗至少2个周期,观察其有效率、生存期和毒副作用。结果:治疗组:可评价病例31例,其中CR0例,PR8例(25.8%),SD12例(38.7%),PD11例(35.5%),总有效率25.8%(8/31);对照组:可评价病例29例,其中CR0例,PR8例(27.6%),SD 12例(41.4%),PD 9例(31.0%),总有效率27.6%(8/29);两组有效率无显著性差异。治疗组和对照组中位生存期分别为7.7个月和8.3个月,1年生存率分别为34.4%和41.4%,两组比较无显著性差异。毒副作用主要为中性粒细胞下降、肝功能损伤、神经毒性、恶心、呕吐、腹泻等,多表现为Ⅰ、Ⅱ度,治疗组的腹泻发生率显著高于对照组;Ⅲ、Ⅳ度反应主要为中性粒细胞下降及神经毒性,治疗组发生率显著低于对照组。没有出现治疗相关性死亡。结论:CPT-11/5-FU/LV静滴给药是治疗进展期胃癌的有效化疗手段,毒性反应较低,但合理剂量和疗程还需进一步的大样本治疗观察。

English Abstract

Clinical study on combination chemotherapy with irinotecan,fluorouracil,and leucovorin in patients with advanced gastric carcinoma

Department of General Surgery, 411th Hospital, PLA, Shanghai 200081, China

Received Date: 2009-03-18

Keywords:

Abstract: Objective :To investigate the efficacy and safety of irinotecan(CPT-11) plus fluorouracil(5-FU) and leucovorin(LV) in patients with advanced gastric carcinoma,in reference to those of paclitaxel(TAX) and cisplatin(DDP) combined with 5-FU and LV. Methods :63 Patients with untreated advanced gastric carcinoma were randomly enrolled into treatment group and control group.The treatment group were treated with CTP-11 200 mg on day 1,LV 200 mg and 5-FU 500 mg on day 1～5 while the control group were given TAX 180 mg on day 1,DDP 60mg on day 3,LV 200 mg and 5-FU 500 mg on day 1～5.Both regimens were repeated every 3 weeks.All the patients received at least two treatments and were evaluable for response rate,survival time,and adverse effect. Results :In 31 evaluable patients in treatment group,CR 0 case,PR 8 cases(25.8 %),SD 12 cases(38.7 %),and PD 11 cases(35.5 %).The response rate was 25.8 %(8/31).In 29 evaluable patients in control group,CR 0 case,PR 8 cases(27.6 %),SD 12 cases(41.4 %),and PD 9 cases(31.0 %).The response rate was 25.8 %(8/31).No significant difference was found in terms of response rate between two groups.The median survival and 1-year survival rates were 7.7 and 8.3 months,and 34.4 % and 41.4 % for both groups,respectively.There was no significant difference between two groups.The most common drug-related adverse effects,mainly grade Ⅰ and Ⅱ,included neutropenia,hepatic toxicity,neurotoxicity,diarrhea,nausea,and vomiting.The incidence rate of diarrhea in treatment group was significantly higher than that in control group.Adverse effects of grade Ⅲ and Ⅳ rested on neutropenia and neurotoxicity,and the incidence rate in treatment group was significantly lower than that in control group.No treatment-related death occurred. Conclusion :Intravenous drip of CPT-11/5-FU/LV seems an active approach for untreated advanced gastric carcinoma with tolerated side effects.Further extensive investigations concerning the dose and course of treatment are demand.

孙德好, 邵凌, 刘胜, 陈森林, 曹晓冰. 依立替康/氟尿嘧啶/亚叶酸三药联用治疗晚期胃癌的临床疗效观察[J]. 药学实践与服务, 2009, 27(3): 189-192.

引用本文:

孙德好, 邵凌, 刘胜, 陈森林, 曹晓冰. 依立替康/氟尿嘧啶/亚叶酸三药联用治疗晚期胃癌的临床疗效观察[J]. 药学实践与服务, 2009, 27(3): 189-192.

Citation:

SUN De-hao, SHAO Ling, LIU Sheng, CHEN Seng-lin, CAO Xiao-bing. Clinical study on combination chemotherapy with irinotecan,fluorouracil,and leucovorin in patients with advanced gastric carcinoma[J]. Journal of Pharmaceutical Practice and Service, 2009, 27(3): 189-192.